Sign in

Private company

ASENSUS SURGICAL, INC.

ASENSUS SURGICAL, INC. is an American surgical and medical instruments and apparatus company.1 It is headquartered in Durham, North Carolina.1

Last updated Oct 21, 2026.

Overview

  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersDurham, North Carolina1
  • Incorporated inDE2
  • Business address1 Tw Alexander Drive, Suite 160, Durham, Nc 277032
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

We are a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of surgery, that we refer to as Performance-Guided Surgery™, or PGS, by unlocking clinical intelligence to enable surgeons to deliver consistently superior outcomes to patients. Built upon the foundation of digital laparoscopy and laparoscopic minimally invasive surgery, or MIS, (which remains the gold standard of surgery today), the Company is pioneering PGS to increase surgeon control and reduce surgical variability. With the addition of machine vision, Augmented Intelligence, and deep learning capabilities throughout the surgical experience delivered via the Senhance® Surgical System, combined with the Intelligent Surgical Unit™, or ISU™, we intend to holistically address the current clinical, surgeon performance (fatigue and ergonomics), and economic shortcomings that…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-53.4%Gross margin5
-926.5%Operating margin5
-914.5%Net margin5
21.0%Revenue growth, 20235
-234.7%Return on equity5
-$64.2MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue26¢$13.2M
  • Research and development73¢$37.0M
  • Income tax1¢$314.0K

Out of $8.6M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$8.6M in 2023+21% since 2017
0$10.0M$20.0M$30.0M2017: $7.1M$7.1M20172018: $24.1M$24.1M2018+239%2019: $8.5M$8.5M2019−65%2020: $3.2M$3.2M2020−63%2021: $8.2M$8.2M2021+159%2022: $7.1M$7.1M2022−14%2023: $8.6M$8.6M2023+21%
Gross profit67895-$4.6M in 2023
-$20.0M-$10.0M0$10.0M2017: $384.0K$384.0K20172018: $7.9M$7.9M2018+1965%2019: -$12.2M-$12.2M20192020: -$2.0M-$2.0M2020−84%2021: -$2.9M-$2.9M2021+44%2022: -$3.8M-$3.8M2022+32%2023: -$4.6M-$4.6M2023+21%
Operating income67895-$79.5M in 2023+28% since 2017
-$200.0M-$150.0M-$100.0M-$50.0M02017: -$61.9M-$61.9M20172018: -$49.2M-$49.2M2018−21%2019: -$154.6M-$154.6M2019+214%2020: -$60.4M-$60.4M2020−61%2021: -$64.6M-$64.6M2021+7%2022: -$75.7M-$75.7M2022+17%2023: -$79.5M-$79.5M2023+5%
Net income67895-$78.4M in 2023−46% since 2017
-$200.0M-$150.0M-$100.0M-$50.0M02017: -$144.8M-$144.8M20172018: -$61.8M-$61.8M2018−57%2019: -$154.2M-$154.2M2019+150%2020: -$59.3M-$59.3M2020−62%2021: -$62.5M-$62.5M2021+5%2022: -$75.6M-$75.6M2022+21%2023: -$78.4M-$78.4M2023+4%
Fiscal year2017201820192020202120222023
Revenue$7.1M6$24.1M7$8.5M8$3.2M8$8.2M9$7.1M5$8.6M5
Cost of revenue$6.7M6$16.2M6$20.7M8$5.2M8$11.1M9$10.9M5$13.2M5
Gross profit$384.0K6$7.9M7-$12.2M8-$2.0M8-$2.9M9-$3.8M5-$4.6M5
Research and development$22.0M6$21.8M7$22.5M8$16.6M8$19.3M9$28.9M5$37.0M5
Operating expenses$61.8M9$71.9M5$74.9M5
Operating income-$61.9M6-$49.2M7-$154.6M8-$60.4M8-$64.6M9-$75.7M5-$79.5M5
Interest$2.4M6$4.2M7$3.6M8$19.0K8$370.0K9$410.0K5$05
Income before tax-$62.2M9-$75.2M5-$78.1M5
Income tax-$3.3M6-$3.4M7-$3.1M8-$1.5M8$225.0K9$318.0K5$314.0K5
Net income-$144.8M6-$61.8M7-$154.2M8-$59.3M8-$62.5M9-$75.6M5-$78.4M5
Earnings per share-$0.289-$0.325-$0.315
Shares (weighted, basic)227.0M shares9236.5M shares5249.7M shares5

Compare ASENSUS SURGICAL, INC. with another company

Corporate structure

ASENSUS SURGICAL, INC. sits at the top of its group. 10 entities, 8 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ASENSUS SURGICAL, INC.

  • Beryl Capital Management LLC Filed SC 13G/A on ASENSUS SURGICAL, INC., latest Nov 13, 2024 (2 filings since Jul 15, 2024)
  • State Street Corporation Filed SC 13G/A on ASENSUS SURGICAL, INC., latest Jan 20, 2023 (2 filings since Feb 10, 2022)
  • BlackRock Filed SC 13G on ASENSUS SURGICAL, INC., latest Jul 8, 2022 (2 filings since Feb 4, 2022)
  • ASENSUS SURGICAL, INC. Durham, North Carolina
    • Asensus International, Inc. Subsidiary · Delaware, United States
    • Asensus Surgical Canada, Inc. Subsidiary · Ontario, Canada
    • Asensus Surgical Europe S.à r.l. Subsidiary · Luxembourg
    • Asensus Surgical Israel Ltd Subsidiary · Israel
    • Asensus Surgical Italia, S.r.l. Subsidiary · Italy
    • Asensus Surgical Japan K.K. Subsidiary · Japan
    • Asensus Surgical Netherlands B.V. Subsidiary · Netherlands
    • Asensus Surgical US, Inc. Subsidiary · Delaware, United States
    • Asensus Taiwan Ltd. Subsidiary · Taiwan

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ASENSUS SURGICAL, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$25.0M5 Dec 31, 2023$22.2M5 Dec 31, 2022+12.7%
Accumulated depreciation$16.1M5 Dec 31, 2023$12.7M5 Dec 31, 2022+26.9%
Property and equipment, net$9.0M5 Dec 31, 2023$9.5M5 Dec 31, 2022−6.1%
Operating-lease assets (leased space)$5.2M5 Dec 31, 2023$5.0M5 Dec 31, 2022+4.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$17.1M5 Dec 31, 2023$6.3M5 Dec 31, 2022+170.1%
Marketable securities, current$4.0M5 Dec 31, 2023$64.2M5 Dec 31, 2022−93.8%
Marketable securities, non-current$05 Dec 31, 2023$3.9M5 Dec 31, 2022−100.0%
Debt securities available for sale$4.0M5 Dec 31, 2023$68.1M5 Dec 31, 2022−94.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Finite-lived intangibles, gross$69.2M5 Dec 31, 2023$69.2M5 Dec 31, 20220%
Accumulated amortization$67.2M5 Dec 31, 2023$66.8M5 Dec 31, 2022+0.6%
Finite-lived intangibles, net$1.2M5 Dec 31, 2023$1.6M5 Dec 31, 2022−21.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$7.2M5 Dec 31, 2023$8.3M5 Dec 31, 2022−13.4%
Raw materials$2.0M5 Dec 31, 2023$2.5M5 Dec 31, 2022−20.8%
Finished goods$9.2M5 Dec 31, 2023$11.2M5 Dec 31, 2022−17.9%

Leadership

Who has led ASENSUS SURGICAL, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jeffrey G. Spragens2007–2013
  2. Todd Pope2013–2019
  3. Anthony C. J. Fernando2020–2024

President

  1. Jeffrey G. Spragens2007–2013
  2. Todd Pope2013–2019
  3. Anthony C. J. Fernando2020–2024

Chief financial officer

  1. Adam S. Jackson2008–2010
  2. Joseph P. Slattery2013–2019
  3. Brett Farabaugh2020
  4. Rampertab Shameze2020–2024

Chief operating officer

  1. Stewart B. Davis2007–2010
  2. Richard Mueller2013–2014
  3. Anthony C. J. Fernando2017–2019
2010201520202025
Board members and other officers (24)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Asensus International, Inc. Delaware3
  • Asensus Surgical Canada, Inc. Ontario, Canada3
  • Asensus Surgical Europe S.à r.l. Luxembourg3
  • Asensus Surgical Israel Ltd Israel3
  • Asensus Surgical Italia, S.r.l. Italy3
  • Asensus Surgical Japan K.K. Japan3
  • Asensus Surgical Netherlands B.V. Netherlands3
  • Asensus Surgical US, Inc. Delaware3
  • Asensus Taiwan Ltd. Taiwan3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • TRANSENTERIX, INC.Aug 8, 2019 to Feb 23, 20212
  • TRANSENTERIX INC.Nov 8, 2013 to Jul 10, 20192
  • SafeStitch Medical, Inc.Feb 12, 2008 to Dec 10, 20132
  • CELLULAR TECHNICAL SERVICES CO INCJul 19, 1996 to Feb 11, 20082

Timeline

  1. Aug 22, 20248-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights44
  2. Aug 20, 20248-K Shareholder vote45
  3. Aug 13, 20248-K Results of operations46
  4. Jul 29, 20248-K Other events47
  5. Jun 7, 20248-K Entered a material agreement; Other events48
  6. May 15, 20248-K Director nominations49
  7. May 15, 20248-K Results of operations50
  8. Apr 3, 20248-K Entered a material agreement; New debt or obligation; Change to shareholders' rights51
  9. Mar 25, 20248-K Results of operations52
  10. Jan 8, 20248-K Results of operations53
  11. Jan 4, 20248-K Other events54
  12. Nov 16, 20238-K Results of operations55
  13. Feb 6, 2020New chief executive Anthony C. J. Fernando becomes CEO13
  14. Sep 4, 2013New chief executive Todd Pope becomes CEO14
  15. Sep 6, 2007New chief executive Jeffrey G. Spragens becomes CEO15

Calendar

When it reported results

  1. Aug 13, 2024Reported quarterly or annual results46
  2. May 15, 2024Reported quarterly or annual results50
  3. Mar 25, 2024Reported quarterly or annual results52
  4. Jan 8, 2024Reported quarterly or annual results53
  5. Nov 16, 2023Reported quarterly or annual results55
  6. Aug 11, 2023Reported quarterly or annual results56
  7. May 15, 2023Reported quarterly or annual results57
  8. Mar 2, 2023Reported quarterly or annual results58

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

143 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 36 major events, 38 insider forms, 6 large holders, 50 other. The latest 20:

  1. Nov 13, 2024SC 13G/A EDGAR
  2. Sep 3, 202415-12G EDGAR
  3. Aug 26, 2024EFFECT EDGAR
  4. Aug 26, 2024EFFECT EDGAR
  5. Aug 26, 2024EFFECT EDGAR
  6. Aug 26, 2024EFFECT EDGAR
  7. Aug 26, 2024EFFECT EDGAR
  8. Aug 22, 2024S-8 POS EDGAR
  9. Aug 22, 2024S-8 POS EDGAR
  10. Aug 22, 2024S-8 POS EDGAR
  11. Aug 22, 2024S-8 POS EDGAR
  12. Aug 22, 2024S-8 POS EDGAR
  13. Aug 22, 2024S-8 POS EDGAR
  14. Aug 22, 2024S-8 POS EDGAR
  15. Aug 22, 2024S-8 POS EDGAR
  16. Aug 22, 2024S-8 POS EDGAR
  17. Aug 22, 2024S-8 POS EDGAR
  18. Aug 22, 2024S-8 POS EDGAR
  19. Aug 22, 2024S-8 POS EDGAR
  20. Aug 22, 2024S-8 POS EDGAR

The 143 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 6 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 14, 2023Starling William N JRDirectorBuy18,134$0.28$5.1KForm 4
Dec 14, 2023Starling William N JRDirectorSale18,134$0.28$5.1KForm 4
Mar 3, 2023Biffi AndreaDirectorBuy293,077$0.71$208.1KForm 4
Mar 3, 2023Biffi AndreaDirectorBuy293,077$0.71$208.1KForm 4
Jun 13, 2022Starling William N JRDirectorSale27,010$0.40$10.8KForm 4
Mar 15, 2022Kwo ElizabethDirectorBuy18,000$0.53$9.5KForm 4
Mar 7, 2022Milne David BruceDirectorBuy225,000$0.62$139.7KForm 4
Mar 4, 2022Milne David BruceDirectorBuy150,000$0.64$95.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How ASENSUS SURGICAL, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARASENSUS SURGICAL, INC.1
  • CIK0000876378
  • Employer ID (EIN)11-29620801
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1 Tw Alexander Drive, Suite 160, Durham, NC 277031
  • Phone919-765-84001
  • Shares outstanding272,842,574 as of Aug 6, 202411
  • Public float$120.1M as of Jun 30, 202362
  • On EDGAR sinceMay 15, 19961
  • Filings1,101 in all: 4 (355), 8-K (249), 10-Q (74), 3 (35), SC 13D/A (31), 424B5 (27), SC 13G/A (25), DEF 14A (24)1
    All 55 form types

    10-K (22), DEFA14A (22), CORRESP (17), EFFECT (17), SC 13G (17), S-8 (16), S-8 POS (16), 10QSB (12), UPLOAD (12), S-3 (11), 8-K/A (9), SC 13D (9), D (8), POS AM (8), S-3/A (8), 10-K/A (5), 10KSB/A (5), 424B3 (5), 10KSB (4), 4/A (4), 5 (4), CT ORDER (4), 10QSB/A (3), DEF 14C (3), FWP (3), PRE 14A (3), PRE 14C (3), RW (3), 10-K405 (2), 3/A (2), ARS (2), NT 10-Q (2), REGDEX (2), S-1 (2), S-3MEF (2), SC 14F1 (2), SEC STAFF LETTER (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 424B2 (1), 8-A12B (1), CERTNYS (1), DEFM14A (1), DEFR14A (1), PREM14A (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Mar 21, 2024
    Quarterly report (10-Q) Aug 13, 2024
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Aug 22, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
    SEC EDGAROther events
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
    SEC EDGAROther events
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62